Adverse effects of antipsychotic drugs.

Abstract:

:The side effects of antipsychotic drugs have always been a major concern for clinicians and the appreciation of their importance in the treatment of schizophrenia has increased steadily over the years. Epidemiological studies as well as trials of the prevention and treatment of antipsychotic side effects are the consequences of this development. Results of these studies also have important implications for improving compliance and quality of life in schizophrenic patients. Thus, side effects research has made the treatment of schizophrenia not only safer but also more effective. Next to a brief overview of some of the more important adverse events and their treatment, we will also discuss these effects in the context of compliance, treatment response and the influence of anti-EPS drugs.

authors

Whitworth AB,Fleischhacker WW

doi

10.1097/00004850-199501005-00005

subject

Has Abstract

pub_date

1995-01-01 00:00:00

pages

21-7

eissn

0268-1315

issn

1473-5857

journal_volume

9 Suppl 5

pub_type

杂志文章,评审
  • Tolerability of combined treatment with lithium and fluoxetine: 14 cases treated under open conditions.

    abstract::Fourteen cases of depression resistant to multiple treatments were treated by lithium augmentation of fluoxetine. Tolerability of the treatment was poor. Lithium and fluoxetine may be a possible treatment for resistant depression but there is caution regarding tolerability and toxicity with the relatively high doses o...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199400910-00005

    authors: Hawley CJ,Roberts AG,Baldwin DS

    更新日期:1994-04-01 00:00:00

  • Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide.

    abstract::To compare the efficacy and tolerability of moclobemide versus paroxetine for the treatment of depression with comorbid anxiety disorders. Outpatients fulfilling DSM-III-R criteria for major depression or dysthymia and for a co-occurring comorbid anxiety disorder (panic disorder, generalized anxiety disorder or obsess...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-200301000-00003

    authors: Pini S,Amador XF,Dell'Osso L,Baldini Rossi N,Cassano P,Savino M,Cassano GB

    更新日期:2003-01-01 00:00:00

  • Relationship between insulin resistance and C-reactive protein in a patient population treated with second generation antipsychotic medications.

    abstract::C-reactive protein (CRP) is an inflammatory marker associated with obesity, insulin resistance, and cardiovascular disease. A recent study found CRP levels to be higher in individuals treated with certain antipsychotic medications such as olanzapine; however, it is not clear whether this is associated directly with dr...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e3283400cd3

    authors: Kim SH,Reaven G,Lindley S

    更新日期:2011-01-01 00:00:00

  • Carbamazepine in rapid cycling bipolar affective disorder.

    abstract::Eighteen patients with rapid cycling bipolar affective disorder were recruited for an open trial of carbamazepine. Of these patients all but 2 had been resistant to lithium prophylaxis. Twelve of the patients were able to complete at least 6 months on carbamazepine. Of these 12 patients, 2 had a complete remission of ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-198804000-00003

    authors: Joyce PR

    更新日期:1988-04-01 00:00:00

  • The effects of moclobemide on psychomotor performance and cognitive function.

    abstract::Sixteen young male volunteers received single doses of moclobemide 200 mg, moclobemide 400 mg, amitriptyline 50 mg and placebo in a double-blind crossover study. Subjects then completed a test battery which is sensitive to the effects of psychoactive drugs at 1, 2, and 4 h post-dose. The test battery included tasks of...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199300810-00007

    authors: Fairweather DB,Kerr JS,Hindmarch I

    更新日期:1993-04-01 00:00:00

  • Olanzapine compared to lithium in mania: a double-blind randomized controlled trial.

    abstract::Neuroleptics are of established efficacy in mania. Controlled data on the use of olanzapine in mania is however, absent. In this study, 30 patients meeting DSM-IV criteria for mania were randomly allocated to receive either olanzapine or lithium in a 4 week double-blind randomized controlled design. There were no sign...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199911000-00003

    authors: Berk M,Ichim L,Brook S

    更新日期:1999-11-01 00:00:00

  • Depot antipsychotics in bipolar affective disorder.

    abstract::The effect of prophylactic treatment with depot antipsychotic drugs was examined in 16 patients with bipolar affective disorder. The frequency and duration of illness episodes occurring during depot treatment was compared to that which occurred when these patients were treated with other agents over a corresponding ti...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199300820-00007

    authors: White E,Cheung P,Silverstone T

    更新日期:1993-07-01 00:00:00

  • The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.

    abstract::Depression compromises affected individuals' functional well-being and impairs their level of social and workplace performance. Improved social functioning in depressed patients may improve their work productivity. This study evaluated the differential effects of two antidepressants on social functioning outcomes for ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200015050-00005

    authors: Venditti LN,Arcelus A,Birnbaum H,Greenberg P,Barr CE,Rowland C,Williamson T

    更新日期:2000-09-01 00:00:00

  • Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients.

    abstract::The effect of adjunctive fluoxetine on negative schizophrenic symptoms was evaluated in 34 chronic schizophrenic in-patients on maintenance therapy with neuroleptics. They received randomly, on a double-blind basis, fluoxetine (20 mg/day) or placebo for 12 weeks. In the fluoxetine group, three patients dropped out bec...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199400940-00007

    authors: Spina E,De Domenico P,Ruello C,Longobardo N,Gitto C,Ancione M,Di Rosa AE,Caputi AP

    更新日期:1994-01-01 00:00:00

  • The cognitive abnormalities underlying the symptomatology and the disability of patients with schizophrenia.

    abstract::A variety of cognitive impairments can be observed in patients with schizophrenia, including substantial reductions in the intelligence quotient (IQ). I propose that these impairments can be best understood in terms of the abnormal processes underlying the signs and symptoms manifested by the patient at the time of th...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Frith CD

    更新日期:1995-09-01 00:00:00

  • Effect of trifluoperazine, a potential drug for tuberculosis with psychotic disorders, on the growth of clinical isolates of drug resistant Mycobacterium tuberculosis.

    abstract::The effect of the antipsychotic drug trifluoperazine (TFP) on the in-vitro growth of 50 clinical isolates of Mycobacterium tuberculosis was tested. Of these isolates, 29 were susceptible to all five of the antitubercular drugs isoniazid, rifampicin, streptomycin, ethambutol and pyrazinamide, and 21 were resistant to o...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199805000-00006

    authors: Gadre DV,Talwar V,Gupta HC,Murthy PS

    更新日期:1998-05-01 00:00:00

  • Clozapine-associated neutropenia in Latin America: incidence report of 5380 Chilean users.

    abstract::Systematic information about Latino clozapine users is still scarce. Our aim was to evaluate the risk of clozapine-associated neutropenia in a Chilean cohort using the last Food and Drug Administration's recommendations for clozapine monitoring. Findings should improve clinical practice and promote changes in clozapin...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000270

    authors: Mena CI,Nachar RA,Crossley NA,González-Valderrama AA

    更新日期:2019-09-01 00:00:00

  • Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study.

    abstract::The negative symptoms of schizophrenia remain a major clinical challenge. Reboxetine is an antidepressant whose major mechanism of action is as a noradrenergic reuptake inhibitor. This study was a 6-week randomized placebo-controlled trial of reboxetine or placebo add on to haloperidol 5 mg in the treatment of 30 pati...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-200109000-00004

    authors: Schutz G,Berk M

    更新日期:2001-09-01 00:00:00

  • Carbamazepine compared to haloperidol in acute mania.

    abstract::In a double-blind, between-patient clinical trial carbamazepine (CBZ) (n = 8) was compared to haloperidol (HP) (n = 9) in patients presenting with mania (DSM III). Seven patients on HP and 2 on CBZ failed to complete 4 weeks treatment. In 4 of the HP group this was because of extrapyramidal side-effects (EPS). Two pat...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-198907000-00005

    authors: Brown D,Silverstone T,Cookson J

    更新日期:1989-07-01 00:00:00

  • Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.

    abstract::Recently proposed criteria for remission by a 'Remission in Schizophrenia Working Group' have generated considerable interest. We assessed rates, predictors, and correlates of remission in a sample of patients with first-episode schizophrenia treated with injectable, long-acting risperidone. This allowed us to examine...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/YIC.0b013e32830c2042

    authors: Emsley R,Oosthuizen P,Koen L,Niehaus DJ,Medori R,Rabinowitz J

    更新日期:2008-11-01 00:00:00

  • Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study.

    abstract::Mood stabilizers are used clinically for the management of bipolar disorder. Prophylactic therapy with mood stabilizers is the primary treatment for preventing depressive and manic relapses in bipolar patients once they are stabilized. In this study, we examined the relative efficacy of the three most commonly used mo...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000097

    authors: Peselow ED,Clevenger S,IsHak WW

    更新日期:2016-07-01 00:00:00

  • Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice.

    abstract::Two selective serotonin reuptake inhibitors (SSRIs), citalopram and fluoxetine, both at a daily dose of 20 mg, were compared in patients with unipolar major depression treated in general practice. This was a multicentre, double-blind, randomized trial carried out in France. The duration of treatment was 8 weeks. Patie...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Patris M,Bouchard JM,Bougerol T,Charbonnier JF,Chevalier JF,Clerc G,Cyran C,Van Amerongen P,Lemming O,Høpfner Petersen HE

    更新日期:1996-06-01 00:00:00

  • Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.

    abstract::The treatment of negative symptoms of schizophrenia presents a major clinical challenge. This review examines the evidence pertaining to the efficacy, tolerability and safety of adding selective serotonin reuptake inhibitors (SSRIs) to antipsychotic agents in the treatment of negative symptoms in schizophrenia. Import...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-200311000-00001

    authors: Silver H

    更新日期:2003-11-01 00:00:00

  • The response of untreated chronic schizophrenics to haloperidol and haloperidol decanoate.

    abstract::A group of 13 untreated schizophrenic patients was collected over two and a half years. They were prescribed a standard regime of oral haloperidol, and where possible were transferred to haloperidol decanoate depot injections when their clinical condition stabilised. The progress of their symptoms was monitored weekly...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Leff JP,Tress KH

    更新日期:1986-07-01 00:00:00

  • Quetiapine-induced myoclonus.

    abstract::We report a case of myoclonus induced by quetiapine. A 64-year-old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine. These movements were dose-related and completely abated on reducing the dose. To our knowledge, these movements have not been reported previously as an adverse effe...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200503000-00011

    authors: Velayudhan L,Kirchner V

    更新日期:2005-03-01 00:00:00

  • Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria.

    abstract::Premenstrual dysphoria (PMD) is a severe form of premenstrual syndrome, afflicting approximately 5% of all women of fertile age. The cardinal symptoms are irritability and anger. In addition, sadness, tension and carbohydrate craving are common complaints. The symptoms surface regularly between ovulation and menstruat...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Eriksson E

    更新日期:1999-05-01 00:00:00

  • Prediction of response to acute neuroleptic treatment in schizophrenia.

    abstract::Predicting the outcome of treatment with neuroleptics and understanding the factors that contribute to variability in the response to these drugs have preoccupied researchers and clinicians since the class was developed. Clinicians need empirically based prospective criteria in order to choose a treatment strategy tha...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199605002-00008

    authors: Gaebel W

    更新日期:1996-05-01 00:00:00

  • Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression.

    abstract::Sparse data exist regarding the risks and benefits of treating bipolar-II depression with antidepressants alone. On the basis of studies of bipolar-I patients, treatment guidelines suggest antidepressants should be augmented with mood stabilizers. Whether these recommendations apply to bipolar-II is unclear. A post-ho...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e3280c28410

    authors: Agosti V,Stewart JW

    更新日期:2007-09-01 00:00:00

  • Hyoscine for clozapine-induced hypersalivation: a double-blind, randomized, placebo-controlled cross-over trial.

    abstract::Clozapine is the only evidence-based antipsychotic for treatment-resistant schizophrenia. However, it has considerable side effects, limiting its usability and reducing patients' adherence. One of the most common and distressing side effects is hypersalivation, which can be debilitating, stigmatizing and potentially d...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000251

    authors: Segev A,Evans A,Hodsoll J,Whiskey E,Sheriff RS,Shergill S,MacCabe JH

    更新日期:2019-03-01 00:00:00

  • A molecular pathway analysis informs the genetic risk for arrhythmias during antipsychotic treatment.

    abstract::Arrhythmias are a frequent and potentially fatal side effect of antipsychotic treatment. Strict ECG monitoring and clinical interviews are the standards used to prevent arrhythmias. A biologic predictive tool is missing. The identification of a genetic makeup at risk of antipsychotic-induced arrhythmias is the aim of ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000198

    authors: Drago A,Kure Fischer E

    更新日期:2018-01-01 00:00:00

  • Changes in the platelet intracellular calcium response to serotonin in patients with major depression treated with electroconvulsive therapy: state or trait marker status.

    abstract::Platelet serotonin type 2A receptor (5-HT2A) sensitivity changes have previously been documented in depression, although it is unclear if this represents a stable trait marker of the illness, or whether it represents an acute state marker of depression that would change with treatment. Electroconvulsive therapy (ECT) ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200015020-00005

    authors: Plein H,Berk M

    更新日期:2000-03-01 00:00:00

  • Which antidepressants have demonstrated superior efficacy? A review of the evidence.

    abstract::A review of published evidence of superior efficacy of a particular antidepressant in major depressive disorder may assist clinicians in making considered treatment choices. To identify such candidates, an international group of experts met to assess published evidence (identified through searches in Medline and Embas...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/YIC.0b013e3282eff7e0

    authors: Montgomery SA,Baldwin DS,Blier P,Fineberg NA,Kasper S,Lader M,Lam RW,Lépine JP,Möller HJ,Nutt DJ,Rouillon F,Schatzberg AF,Thase ME

    更新日期:2007-11-01 00:00:00

  • Anticholinergic equivalents and parkinsonism: a model for predicting side-effects of antipsychotic drugs.

    abstract::The tendency of antipsychotics to produce extrapyramidal side-effects varies inversely with their antimuscarinic activity. This paper reviews the antipsychotic and antimuscarinic potency of these drugs and compares the total antimuscarinic activity in standard daily doses of antipsychotics, antiparkinson agents and an...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-198701000-00005

    authors: Menkes DB,Clarkson HO,Caradoc-Davies G,Mullen PE

    更新日期:1987-01-01 00:00:00

  • Toleration and safety of sertraline: experience worldwide.

    abstract::The clinical trial programme of sertraline, a selective serotonin re-uptake inhibitor, has shown the drug to have a favourable safety and toleration profile. In contrast, the tricyclic antidepressant, amitriptyline, produced a significant level of side effects, particularly anticholinergic. The side-effect profile of ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199112002-00007

    authors: Doogan DP

    更新日期:1991-12-01 00:00:00

  • The clinical uses and pharmacology of carbamazepine in psychiatry.

    abstract::Good evidence now exists for a therapeutic action of carbamazepine (CBZ) both in acute mania and in the prophylaxis of manic depression. Comparison with other existing therapies and incidence of adverse effects in psychiatric patients also deserve more clinical research. This paper reviews these clinical issues and th...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-198807000-00001

    authors: Elphick M

    更新日期:1988-07-01 00:00:00